Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546963 | 0.90 | KMT2A (0.57) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL31720093 | 0.87 | TLR2 (0.41) | KMT2ACASP3TLR2 | |
| SCHEMBL31720350 | 0.87 | TLR2 (0.41) | KMT2ACASP3TLR2 | |
| SCHEMBL15669323 | 0.86 | KMT2A (0.68) | KMT2ACASP3TLR2 | |
| SCHEMBL28823765 | 0.86 | KMT2A (0.68) | KMT2ACASP3TLR2 | |
| SCHEMBL31478343 | 0.84 | CASP3 (0.47) | KMT2ACASP3TLR2 | |
| SCHEMBL24728974 | 0.84 | KMT2A (0.56) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL31664707 | 0.84 | KMT2A (0.56) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL29697708 | 0.84 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 | |
| SCHEMBL29603695 | 0.84 | KMT2A (0.51) | KMT2ACASP3TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | KMT2A 443/4885CASP3 3963/4885TLR2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.